223 related articles for article (PubMed ID: 33459068)
1. Inhibitors of prostate-specific membrane antigen in the diagnosis and therapy of metastatic prostate cancer - a review of patent literature.
Ha H; Kwon H; Lim T; Jang J; Park SK; Byun Y
Expert Opin Ther Pat; 2021 Jun; 31(6):525-547. PubMed ID: 33459068
[TBL] [Abstract][Full Text] [Related]
2. Novel β- and γ-Amino Acid-Derived Inhibitors of Prostate-Specific Membrane Antigen.
Kim K; Kwon H; Barinka C; Motlova L; Nam S; Choi D; Ha H; Nam H; Son SH; Minn I; Pomper MG; Yang X; Kutil Z; Byun Y
J Med Chem; 2020 Mar; 63(6):3261-3273. PubMed ID: 32097010
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, radiolabeling and biological evaluation of new urea-based peptides targeting prostate specific membrane antigen.
Mosayebnia M; Hajimahdi Z; Beiki D; Rezaeianpour M; Hajiramezanali M; Geramifar P; Sabzevari O; Amini M; Hatamabadi D; Shahhosseini S
Bioorg Chem; 2020 Jun; 99():103743. PubMed ID: 32217372
[TBL] [Abstract][Full Text] [Related]
4. Dipeptide inhibitors of the prostate specific membrane antigen (PSMA): A comparison of urea and thiourea derivatives.
Young JD; Ma MT; Eykyn TR; Atkinson RA; Abbate V; Cilibrizzi A; Hider RC; Blower PJ
Bioorg Med Chem Lett; 2021 Jun; 42():128044. PubMed ID: 33865971
[TBL] [Abstract][Full Text] [Related]
5. Current Status of Prostate-Specific Membrane Antigen Targeting in Nuclear Medicine: Clinical Translation of Chelator Containing Prostate-Specific Membrane Antigen Ligands Into Diagnostics and Therapy for Prostate Cancer.
Kratochwil C; Afshar-Oromieh A; Kopka K; Haberkorn U; Giesel FL
Semin Nucl Med; 2016 Sep; 46(5):405-18. PubMed ID: 27553466
[TBL] [Abstract][Full Text] [Related]
6. Design of a Small-Molecule Drug Conjugate for Prostate Cancer Targeted Theranostics.
Kumar A; Mastren T; Wang B; Hsieh JT; Hao G; Sun X
Bioconjug Chem; 2016 Jul; 27(7):1681-9. PubMed ID: 27248781
[TBL] [Abstract][Full Text] [Related]
7. Glutamate-urea-based PSMA-targeted PLGA nanoparticles for prostate cancer delivery of docetaxel.
Saniee F; Shabani Ravari N; Goodarzi N; Amini M; Atyabi F; Saeedian Moghadam E; Dinarvand R
Pharm Dev Technol; 2021 Apr; 26(4):381-389. PubMed ID: 33538232
[TBL] [Abstract][Full Text] [Related]
8. Radiolabeled enzyme inhibitors and binding agents targeting PSMA: Effective theranostic tools for imaging and therapy of prostate cancer.
Pillai MRA; Nanabala R; Joy A; Sasikumar A; Russ Knapp FF
Nucl Med Biol; 2016 Nov; 43(11):692-720. PubMed ID: 27589333
[TBL] [Abstract][Full Text] [Related]
9. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging.
Eder M; Schäfer M; Bauder-Wüst U; Hull WE; Wängler C; Mier W; Haberkorn U; Eisenhut M
Bioconjug Chem; 2012 Apr; 23(4):688-97. PubMed ID: 22369515
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and preliminary evaluation of
Vaidyanathan G; Mease RC; Minn I; Choi J; Chen Y; Shallal H; Kang CM; McDougald D; Kumar V; Pomper MG; Zalutsky MR
Nucl Med Biol; 2021; 94-95():67-80. PubMed ID: 33601187
[TBL] [Abstract][Full Text] [Related]
11. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
Umbricht CA; Benešová M; Schibli R; Müller C
Mol Pharm; 2018 Jun; 15(6):2297-2306. PubMed ID: 29684274
[TBL] [Abstract][Full Text] [Related]
12. Novel multifunctional
Kwon YD; Lee JY; La MT; Lee SJ; Lee SH; Park JH; Kim HK
Eur J Med Chem; 2020 Mar; 189():112099. PubMed ID: 32014792
[TBL] [Abstract][Full Text] [Related]
13. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer.
Hillier SM; Maresca KP; Lu G; Merkin RD; Marquis JC; Zimmerman CN; Eckelman WC; Joyal JL; Babich JW
J Nucl Med; 2013 Aug; 54(8):1369-76. PubMed ID: 23733925
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and Radiolabeling of Glu-Urea-Lys with
Hatamabadi D; Joukar S; Shakeri P; Balalaie S; Yazdani A; Khoramjouy M; Mazidi SM; Kobarfard F; Mosayebnia M; Bozorgchami N; Ahmadi M; Ayyoubzadeh SM; Shahhosseini S
Cancer Biother Radiopharm; 2023 Sep; 38(7):486-496. PubMed ID: 37578479
[No Abstract] [Full Text] [Related]
15. Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand.
Kularatne SA; Wang K; Santhapuram HK; Low PS
Mol Pharm; 2009; 6(3):780-9. PubMed ID: 19361233
[TBL] [Abstract][Full Text] [Related]
16. PSMA-11-Derived Dual-Labeled PSMA Inhibitors for Preoperative PET Imaging and Precise Fluorescence-Guided Surgery of Prostate Cancer.
Baranski AC; Schäfer M; Bauder-Wüst U; Roscher M; Schmidt J; Stenau E; Simpfendörfer T; Teber D; Maier-Hein L; Hadaschik B; Haberkorn U; Eder M; Kopka K
J Nucl Med; 2018 Apr; 59(4):639-645. PubMed ID: 29191856
[TBL] [Abstract][Full Text] [Related]
17. PSMA-targeted dendrimers: a patent evaluation (WO2012078534).
Akhtar NH; Osborne JR; Fareedy SB; Tagawa ST
Expert Opin Ther Pat; 2013 May; 23(5):665-8. PubMed ID: 23581819
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and Biologic Evaluation of Novel 18F-Labeled Probes Targeting Prostate-Specific Membrane Antigen for PET of Prostate Cancer.
Harada N; Kimura H; Onoe S; Watanabe H; Matsuoka D; Arimitsu K; Ono M; Saji H
J Nucl Med; 2016 Dec; 57(12):1978-1984. PubMed ID: 27417647
[TBL] [Abstract][Full Text] [Related]
19. Enzymatic radiosynthesis of a
Lowe PT; Dall'Angelo S; Fleming IN; Piras M; Zanda M; O'Hagan D
Org Biomol Chem; 2019 Feb; 17(6):1480-1486. PubMed ID: 30681115
[TBL] [Abstract][Full Text] [Related]
20. Design of Internalizing PSMA-specific Glu-ureido-based Radiotherapeuticals.
Wüstemann T; Bauder-Wüst U; Schäfer M; Eder M; Benesova M; Leotta K; Kratochwil C; Haberkorn U; Kopka K; Mier W
Theranostics; 2016; 6(8):1085-95. PubMed ID: 27279903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]